Gilead Sciences | GILD - Debt



Gilead Sciences reported $24.95B in Debt for its fiscal quarter ending in March of 2025.

Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Agios Pharmaceuticals USD 48.76M 48.76M Jun/2025
ALKERMES USD 72.68M 72.68M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amgen USD 57.38B 2.72B Mar/2025
Biogen USD 6.59B 296.8M Jun/2025
BioMarin Pharmaceutical USD 595.65M 585K Mar/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Eli Lilly USD 38.52B 4.87B Mar/2025
Gilead Sciences USD 24.95B 1.76B Mar/2025
GlaxoSmithKline GBP 17.35B 1.08B Jun/2025
Glaxosmithkline GBP 16.99B 927M Dec/2024
Incyte USD 42.41M 5.29M Jun/2025
J&J USD 52.25B 15.62B Mar/2025
Merck USD 34.84B 2.27B Mar/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 31.27B 12M Mar/2025
Pfizer USD 62.11B 2.24B Mar/2025
PTC Therapeutics USD 2.4B 17.29M Mar/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Sanofi 22.28B 1.24B Jun/2025
Sarepta Therapeutics USD 1.14B 1.16M Mar/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.65B 1.54B Mar/2025